Carl Nicolino
Plus aucun poste en cours
Profil
Carl Nicolino worked as a Principal at Becton, Dickinson & Co. and as a Head of Business Development at Sumitomo Pharma America, Inc. and Warner-Lambert Co. He also worked as a Principal at BBN Corp., a Member at Labopharm, Inc., and as a Head of Business Development at Theratechnologies, Inc. Nicolino served as a Vice President of Business Development at Guardian Medical Solutions Ltd.
and Allostera Pharma, Inc. from 2010 to 2013.
He was also the Head of Business Development at Parke-Davis Canada, Inc. Nicolino holds an MBA from the University of Pennsylvania and an undergraduate degree from Brooklyn College.
Anciens postes connus de Carl Nicolino
| Sociétés | Poste | Fin |
|---|---|---|
Allostera Pharma, Inc.
 Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | Corporate Officer/Principal | 09/09/2013 |
| BECTON, DICKINSON AND COMPANY | Corporate Officer/Principal | - |
BBN Corp.
 BBN Corp. Information Technology ServicesTechnology Services Part of Verizon Communications, Inc., BBN Corp. is a company that offers summer programs for pre-k through 12th grade in Cambridge, MA. Campers can explore all camps by age, date, and interest and register online. The company is known for its special and theme days offered throughout camp, including Wow Wednesdays, Theme Thursdays, and events on Fun Fridays. Last year, 98% of camp families said they would recommend summer camp at BB&N to their friends. BBN was acquired by GTE Corp. on August 15, 1997 for $615.45 million. | Corporate Officer/Principal | - |
Labopharm, Inc.
 Labopharm, Inc. BiotechnologyHealth Technology Labopharm, Inc. discovers and develops drugs. The company was founded in 1990 and is headquartered in Montreal, Canada. | Corporate Officer/Principal | - |
Sumitomo Pharma America, Inc.
 Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 1984 and is headquartered in Marlborough, MA. | Corporate Officer/Principal | - |
Formation de Carl Nicolino
| University of Pennsylvania | Masters Business Admin |
| Brooklyn College | Undergraduate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BECTON, DICKINSON AND COMPANY | Health Technology |
| THERATECHNOLOGIES INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 1984 and is headquartered in Marlborough, MA. | Health Technology |
Warner-Lambert Co.
 Warner-Lambert Co. Pharmaceuticals: MajorHealth Technology Warner-Lambert Co. used to manufacture and market pharmaceuticals, consumer health care products & confectionery. Its pharmaceutical products were ethical pharmaceuticals, biological products and hard-gelatin capsules. Its consumer health products were a wide range of products like oral care mouthwash/dental rinses, toothpaste, effervescent denture cleaning tablets, upper respiratory cold & sinus preparations, antihistamines, allergy products and cough syrups/suppressants. The company was headquartered in Morris Plains, NJ. | Health Technology |
BBN Corp.
BBN Corp. Information Technology ServicesTechnology Services Part of Verizon Communications, Inc., BBN Corp. is a company that offers summer programs for pre-k through 12th grade in Cambridge, MA. Campers can explore all camps by age, date, and interest and register online. The company is known for its special and theme days offered throughout camp, including Wow Wednesdays, Theme Thursdays, and events on Fun Fridays. Last year, 98% of camp families said they would recommend summer camp at BB&N to their friends. BBN was acquired by GTE Corp. on August 15, 1997 for $615.45 million. | Technology Services |
Labopharm, Inc.
Labopharm, Inc. BiotechnologyHealth Technology Labopharm, Inc. discovers and develops drugs. The company was founded in 1990 and is headquartered in Montreal, Canada. | Health Technology |
Guardian Medical Solutions Ltd.
 Guardian Medical Solutions Ltd. Pharmaceuticals: MajorHealth Technology Guardian Medical Solutions Ltd. engages in the development and commercialization of biopharmaceutical products. The company was founded by Michael Anthony Quinn and Felix de la Iglesia on September 19, 2002 and is headquartered in Sydney, Australia. | Health Technology |
Allostera Pharma, Inc.
Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | Distribution Services |
| Parke-Davis Canada, Inc. |
